List view / Grid view
This article summarises the development and testing of a novel vaccine that could be personalised for the treatment of immunotherapy-resistant cancers, such as triple-negative breast cancer (TNBC).
Researchers say this is the first time that CRISPR-Cas9 gene editing has been used to treat cancer effectively in a living animal and that the technique could be revolutionary.
Hamster challenge study results suggests the oral COVID-19 vaccine induces a robust immune response, protecting the animals from infection.
Researchers demonstrate that inhibiting the LMTK3 kinase is an effective anticancer strategy in murine models of breast cancer.
The non-human primate model exhibited a COVID-19-like disease and showed how symptoms and viral activity change over the course of SARS-CoV-2 infection.
The synthetic protein nanoparticle can cross the blood-brain barrier and deliver a targeted therapeutic to glioblastoma cells, say researchers.
Using their de novo protein design strategy, researchers engineered human angiotensin converting enzyme 2 (hACE2) protein decoys that can protect cells from SARS-CoV-2 infection.
After viral pneumonia in elderly mice, there is an accumulation of dysfunctional tissue-resident memory T cells in the lungs which scientists suggest may drive chronic inflammation and fibrosis.
Scientists have developed a drug-like molecule to target amyloid-beta, a disordered protein implicated in Alzheimer's disease that has been considered undruggable.
By blocking the lymphotoxin beta receptor signalling pathway, researchers were able to prevent COPD progression and induce a full restoration of lung tissue.
Certain sensory neurons and Substance P are potential drug targets for the development of novel allergy preventions or treatments, according to scientists.
The scientists developed a therapy which uses nanobiologics to train the innate immune system to recognise and combat cancer cells.
When delivered intranasally, the anti-inflammatory drug VX-765 prevented axon demyelination and loss in a murine model of multiple sclerosis (MS).
Scientists who developed the E22W42 DC vaccine suggest it could be safer and more effective than previous anti-amyloid Alzheimer’s therapies.
Topical delivery of a small interfering RNA (siRNA) using an ionic liquid complex significantly reduced levels of inflammatory cytokines and symptoms of psoriasis.
